Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis

US7811812B2 · kind B2 · utility

Assignee

• Novartis Vaccines and Diagnostics, Inc. · US

Inventors

• Thomas W. Dubensky, Jr. · Piedmont, US
• John Polo · Hayward, US
• Barbara A. Belli · San Diego, US
• Sondra Schlesinger · University City, US
• Sergey A. Drvga · Fort Collins, US
• Ilya Frolov · Birmingham, US

Key dates

• Filing date: Mar 17, 2003
• Grant date: Oct 12, 2010
• Expiry date: Aug 4, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/44
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.